Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status

Clinical Lung Cancer

Volumn 14, Issue 6, 2013, Pages 680-687

  Dong, Xiaopeng ^a   Zhao, Xiaogang ^a   Hao, Yingtao ^a   Wei, Yucheng ^b   Yin, Qiuwei ^c   Du, Jiajun ^d  

^a THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^b QINGDAO UNIVERSITY MEDICAL COLLEGE   (China)

^c SHANDONG UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Chemotherapy; EGFR mutation; K RAS mutation; NSCLC

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DISEASE CONTROL; FEMALE; GENE MUTATION; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE K RAS; PROGRESSION FREE SURVIVAL;

CHEMOTHERAPY; EGFR MUTATION; K-RAS MUTATION; NSCLC;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; DNA MUTATIONAL ANALYSIS; FEMALE; GENES, ERBB-1; GENES, RAS; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; RETROSPECTIVE STUDIES; TAXOIDS; VINBLASTINE;

EID: 84887215068     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.05.004     Document Type: Article

References (29)

1. D.G. Pfister, D.H. Johnson, and C.G. Azzoli American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330 353
2. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
3. G.V. Scagliotti, F. De Marinis, and M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291
4. K. Kelly, J. Crowley, and P.A. Bunn Jr. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218
5. M. Fukuoka, S. Yano, and G. Giaccone Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) J Clin Oncol 21 2003 2237 2246
6. K. Nishie, T. Kawaguchi, and A. Tamiya Epidermal growth factor receptor tyrosine kinase inhibitors beyond progressive disease: a retrospective analysis for Japanese patients with activating EGFR mutations J Thorac Oncol 7 2012 1722 1727
7. F. Petrelli, K. Borgonovo, and M. Cabiddu Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small-cell lung cancer: a meta-analysis of 13 randomized trials Clin Lung Cancer 2 2012 107 114
8. G. Giaccone, R.S. Herbst, and C. Manegold Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1 J Clin Oncol 22 2004 777 784
9. U. Gatzemeier, A. Pluzanska, and A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552
10. C. Mascaux, N. Iannino, and B. Martin The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139
11. W. Pao, T.Y. Wang, and G.J. Riely KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib PLoS Med 2 2005 e17
12. E. Massarelli, M. Varella-Garcia, and X. Tang KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer Clin Cancer Res 13 2007 2890 2896
13. D.A. Eberhard, B.E. Johnson, and L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
14. R. Pirker, J.R. Pereira, and J. von Pawel EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Lancet Oncol 1 2012 33 42
15. K. Hotta, K. Kiura, and S. Toyooka Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer J Thorac Oncol 2 2007 632 637
16. F. Cappuzzo, C. Ligorio, and L. Toschi EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) J Thorac Oncol 2 2007 423 429
17. K.H. Lee, S.W. Han, and P.G. Hwang Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer Jpn J Clin Oncol 36 2006 344 350
18. T. Takano, T. Fukui, and Y. Ohe EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan J Clin Oncol 26 2008 5589 5595
19. T. Yoshimasu, S. Oura, and F. Ohta Epidermal growth factor receptor mutations are associated with docetaxel sensitivity in lung cancer J Thorac Oncol 6 2011 1658 1662
20. M. Dixit, J.L. Yang, and M.C. Poirier Abrogation of cisplatin-induced programmed cell death in human breast cancer cells by epidermal growth factor antisense RNA J Natl Cancer Inst 89 1997 365 373
21. A. Kalikaki, A. Koutsopoulos, and D. Hatzidaki Clinical outcome of patients with non-small cell lung cancer receiving front-line chemotherapy according to EGFR and K-RAS mutation status Lung Cancer 69 2010 110 115
22. J.L. Guan, W.Z. Zhong, and S.J. An KRAS mutation in patients with lung cancer: a predictor for poor prognosis but not for EGFR-TKIs or chemotherapy Ann Surg Oncol 4 2013 1381 1388
23. J.H. Park, S.H. Lee, and B. Keam EGFR mutations as a predictive marker of cytotoxic chemotherapy Lung Cancer 77 2012 433 437
24. J.Y. Douillard, F.A. Shepherd, and V. Hirsh Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial J Clin Oncol 28 2010 744 752
25. N. Karachaliou, C. Costa, and A. Gimenez-Capitan BRCA1, LMO4, and CtIP mRNA expression in erlotinib-treated non-small-cell lung cancer patients with EGFR mutations J Thorac Oncol 3 2013 295 300
26. J.A. Roth, and J.J. Carlson Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis Clin Lung Cancer 6 2011 393 401
27. C. Papadaki, M. Sfakianaki, and G. Ioannidis ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer J Thorac Oncol 7 2012 663 671
28. K.A. Olaussen, A. Dunant, and P. Fouret DNA repair by ERCC1 in non-small cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
29. C. Reynolds, C. Obasaju, and M.J. Schell Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer J Clin Oncol 27 2009 5808 5815